摘要
疟疾是当今世界人类最严重的三大传染性疾病之一。根据疟原虫复杂的生活史和不同发育时期表达特异性抗原分子的特点 ,确定有效特异性候选抗原成为疟疾疫苗研制开发的关键。多年来 ,研究者致力于子孢子疫苗、红内期疫苗和传播阻断疫苗的研究。在我国间日疟分布最广 ,普遍流行。目前 ,对间日疟疫苗候选抗原的研究取得了卓有成效的进展。疫苗已在小鼠、家兔和猴等开展试验 ,有些已进入人体临床实验阶段。该文选择间日疟 3个疫苗阶段有代表性的候选抗原 ,就分子结构 ,免疫原性和免疫效果作一综述。
出处
《国外医学（寄生虫病分册）》
2005年第2期69-72,共4页
Parasitic Diseases Foreign Medical Sciences
基金
国家自然科学基金资助项目 (3 0 3 713 47间日疟原虫传播阻断疫苗候选蛋白Pvs2 5和Pvs2 8疫苗效果的研究 )
参考文献23
-
1Hoffman SL, Doolan DL. Malaria vaccines-targeting infected hepatocytes. Nat Med, 2000,6(11): 1218-1219.
-
2Doolan DL, Hoffman SL. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol, 1999,163(2):884-892.
-
3Le TP, Coonan KM, Hedstrom RC, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine, 2000,18(18):1893-1901.
-
4Joshi H. Markers for population genetic analysis of human plasmodia species P. falciparum and P. vivax. J Vector Borne Dis,2003,40 ( 3-4 ): 78-83.
-
5Udhayakumar V, Saekhou A, Fang S, et al. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC). Vaccine,1998,16(9-10) :982-988.
-
6Oliveira-Ferreira J, Pratt-Riccio LR, Arruda M, et al. HLA class Ⅱ and antibody responses to circumsporozoite protein repeats of P.vivax (VK210, VK247 and P. vivax-like) in individuals naturally exposed to malaria. Acta Trop, 2004,92(1):63-69.
-
7Herrera S, De Plata C, Gonzalez M, et al. Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P.vivax CS epitopes in Aotus monkeys. Parasite Immunol, 1997,19(4):161-170.
-
8Lim KJ, Park JW, Yeom JS, et al. Humoral responses against the C-terminal region of merozoite surface protein 1 can be remembered for more than 30 years in persons exposed to Plasmodium vivax.Parasitol Res, 2004,92(5) :384-389.
-
9Sierra AY, Barrero CA, Rodriguez R, et al. Splenectomised and spleen intact Aotus monkeys' immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. Vaccine, 2003,21(27-30) :4133-4144.
-
10Rosa DS, Tzelepis F, Cunha MG, et al. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett, 2004,92(3) :259-268.
同被引文献24
-
1刘军,冯辉,金行一,曹雅明.我国分离株间日疟原虫与红细胞黏附关键区DBPⅡ区基因多态性分析[J].中国人兽共患病杂志,2005,21(4):323-325. 被引量：2
-
2徐卫民,金行一,曹雅明,郑丽,姚立农,王衡.间日疟原虫疫苗候选抗原Pvs25的基因分析[J].浙江预防医学,2005,17(10):4-5. 被引量：1
-
3Mueller I, Galinski MR, Baird JK, et al. Key gaps in knowledge of Plasmodium vivax, a neglected human malaria parasite [ J ]. Lancet In- feet Dis, 2009, 9(9):555-566.
-
4Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children[J].N Engl J Med, 2011,365(20) : 1863-1875.
-
5Batchelor JD, Zahm JA, Tolia NH. Dimerization ofPlasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC [J]. Nat Struct Mol Biol, 2011, 18(8) :908-914.
-
6Fang XD, Kaslow DC, Adams JH, et al. Cloning of the Plasmodium vivax Duffy receptor[J]. Mol Biochem Parasitol, 1991, 44(1) : 125- 132.
-
7Chitnis CE, Chaudhuri A, Horuk R, et al. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi ma- larial parasites to erythrocytes [J]. J Exp Med, 1996, 184 (4) : 1531-1536.
-
8Michon P, Fraser T, Adams JH. Naturally acquired and vaccine-elic- ited antibodies block erytbroeyte eytoadherence of the Plasmodium vivax Duffy binding protein[J]. Infect Immune, 2000, 68(6) :3164- 3171.
-
9Xainli J, Baisor M, Kastens W, et al. Age-dependent cellular im- mune responses to Plasmodium vivax Duffy binding protein in humans [J]. J Immunol, 2002, 169(6) :3200-3207.
-
10Chitnis CE, Sharma A. Targeting the Plasmodium vivax Duffy-bind- ing protein[J]. Trends Parasitol, 2008, 24( 1 ) : 29-34.
引证文献2
-
1刘丹,夏惠,陶志勇,陈勇,方强,王雪梅,孙新,高颖,买月琴.中国中部地区间日疟原虫分离株Duffy血型结合蛋白Ⅱ区的克隆表达与初步鉴定[J].中国血吸虫病防治杂志,2012,24(4):474-477.
-
2李娜,胡光春,刘岚铮,杨月莲.疟疾疫苗主要候选抗原的研究进展[J].智慧健康,2019,0(26):85-87. 被引量：3
二级引证文献3
-
1张慧君.1例疟疾患者的个案护理查房[J].智慧健康,2020(31):122-124. 被引量：2
-
2王锐.疟疾传播媒介蚊虫调查及其病原检测结果分析[J].中国卫生产业,2021,18(4):169-172.
-
3李娜,刘铭,刘岚铮,白爱英,关恒云,刘辉.间日疟原虫传播阻断疫苗新型候选抗原Pvs48T.B细胞表位的预测与分析[J].智慧健康,2021,7(2):26-28.
-
1潘卫庆,陆德如.恶性疟原虫红内期疫苗研究进展[J].国外医学（寄生虫病分册）,1992,19(4):149-152.
-
2杜津,王东旭,程莉.疟疾疫苗的研究进展[J].国际流行病学传染病学杂志,2008,35(3):215-216.
-
3张本光,刘丽娟,公茂庆.疟疾传播阻断疫苗的研究进展[J].中国媒介生物学及控制杂志,2010,21(6):627-630.
-
4余蕾,李菊升,余文祥,李崇珍,李学忠.抗人间日疟原虫子孢子单克隆抗体的研制及初步鉴定[J].中国寄生虫病防治杂志,1993,6(3):207-207.
-
5管惟滨,孙树权.恶性疟原虫红内期疫苗的研究现状和展望[J].寄生虫与医学昆虫学报,1995,2(4):251-254.
-
6管惟滨,钱锋,陈志辉.疟疾红内期疫苗[J].热带病与寄生虫学,2003,1(1):46-52.
-
7舌下含服，无创脱敏是趋势[J].中国家庭医生,2008(5):10-10.
-
8王有国.计划外的疫苗该不该打[J].家庭健康（医学科普）,2005(9):38-38.
-
9曾令兵,张云怡,秦金红.钩端螺旋体蛋白质组学研究进展[J].国际流行病学传染病学杂志,2010,37(4):276-278.
-
10牛林艳,黄金.同伴教育在糖尿病健康教育中的应用现状[J].中华护理杂志,2014,49(1):79-82. 被引量：201
